Literature DB >> 21331763

Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Hirokazu Takahashi1, Toshihiko Mizuta, Yuichiro Eguchi, Yasunori Kawaguchi, Takuya Kuwashiro, Satoshi Oeda, Hiroshi Isoda, Noriko Oza, Shinji Iwane, Kenichi Izumi, Keizou Anzai, Iwata Ozaki, Kazuma Fujimoto.   

Abstract

BACKGROUND: Several epidemiological studies have reported that diabetes mellitus is a risk factor for hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-positive patients. However, it is unclear whether or not post-challenge hyperglycemia is a risk factor. The purpose of this study was to determine the association between post-challenge hyperglycemia and hepatocarcinogenesis in HCV-positive patients.
METHODS: A total of 203 HCV-RNA-positive subjects (108 males, mean age 54.3 ± 10.8 years; 95 females, mean age 56.6 ± 10.3 years; genotype 1b/2a/2b/3a: 152/38/12/1) who underwent liver biopsy and a 75-g oral glucose tolerance test, and who were treated with interferon (IFN) were enrolled in this study. None of the subjects had been treated with antidiabetic drugs. The subjects underwent ultrasonography and/or computed tomography every 6 months after the end of the IFN therapy.
RESULTS: Thirteen patients, including one patient who achieved a sustained viral response (SVR) with IFN, developed HCC. On multivariate analysis, male sex, age >65 years, excessive alcohol consumption, non-SVR, liver steatosis area >5% in liver specimens, and 120-min post-challenge hyperglycemia were risk factors for the development of HCC. After matching subjects for sex, age, alcohol intake, and response to the IFN therapy, advanced fibrosis stages [hazard ratio (HR) 2.8], liver steatosis (HR 5.4), and 120-min post-challenge hyperglycemia (HR 4.9) were significant risk factors for the development of HCC. Furthermore, after matching for the fibrosis stage, liver steatosis (HR 5.7) and 120-min post-challenge hyperglycemia (HR 6.9) remained as significant factors for HCC development.
CONCLUSION: Post-challenge hyperglycemia is an independent risk factor for HCC in HCV-positive patients.

Entities:  

Mesh:

Year:  2011        PMID: 21331763     DOI: 10.1007/s00535-011-0381-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  39 in total

1.  Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c.

Authors:  C Ito; R Maeda; S Ishida; H Sasaki; H Harada
Journal:  Diabetes Res Clin Pract       Date:  2000-12       Impact factor: 5.602

2.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin.

Authors:  T Nakagami
Journal:  Diabetologia       Date:  2004-02-18       Impact factor: 10.122

3.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).

Authors:  G Fattovich; G Giustina; F Degos; G Diodati; F Tremolada; F Nevens; P Almasio; A Solinas; J T Brouwer; H Thomas; G Realdi; R Corrocher; S W Schalm
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

4.  Hemoglobin A1c in predicting progression to diabetes.

Authors:  Tomoko Nakagami; Naoko Tajima; Toshihide Oizumi; Shigeru Karasawa; Kiriko Wada; Wataru Kameda; Shinji Susa; Takeo Kato; Makoto Daimon
Journal:  Diabetes Res Clin Pract       Date:  2009-11-28       Impact factor: 5.602

5.  Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.

Authors:  Joel R Pekow; Atul K Bhan; Hui Zheng; Raymond T Chung
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

6.  Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia.

Authors:  Q Qiao; J Lindström; T T Valle; J Tuomilehto
Journal:  Diabet Med       Date:  2003-12       Impact factor: 4.359

7.  Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus.

Authors:  Ichiro Konishi; Yoichi Hiasa; Syuichiro Shigematsu; Masashi Hirooka; Shinya Furukawa; Masanori Abe; Bunzo Matsuura; Kojiro Michitaka; Norio Horiike; Morikazu Onji
Journal:  Liver Int       Date:  2009-04-28       Impact factor: 5.828

8.  Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease.

Authors:  L Cacciatore; G Cozzolino; M G Giardina; F De Marco; L Sacca; P Esposito; G Francica; A Lonardo; M Matarazzo; A Varriale
Journal:  Diabetes Res       Date:  1988-04

Review 9.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

10.  Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities.

Authors:  Marcello Persico; Mario Masarone; Vincenzo La Mura; Eliana Persico; Francesco Moschella; Monica Svelto; Savino Bruno; Roberto Torella
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

View more
  14 in total

1.  Diabetes, insulin and cancer risk.

Authors:  Xi-Lin Yang; Juliana Cn Chan
Journal:  World J Diabetes       Date:  2012-04-15

Review 2.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.

Authors:  Yukio Osaki; Yoshihide Ueda; Hiroyuki Marusawa; Jun Nakajima; Toru Kimura; Ryuichi Kita; Hiroki Nishikawa; Sumio Saito; Shinichiro Henmi; Azusa Sakamoto; Yuji Eso; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2011-11-23       Impact factor: 7.527

Review 4.  Diabetes and cancer: Associations, mechanisms, and implications for medical practice.

Authors:  Chun-Xiao Xu; Hong-Hong Zhu; Yi-Min Zhu
Journal:  World J Diabetes       Date:  2014-06-15

Review 5.  Diabetes mellitus and metformin in hepatocellular carcinoma.

Authors:  Koji Fujita; Hisakazu Iwama; Hisaaki Miyoshi; Joji Tani; Kyoko Oura; Tomoko Tadokoro; Teppei Sakamoto; Takako Nomura; Asahiro Morishita; Hirohito Yoneyama; Tsutomu Masaki
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

6.  Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.

Authors:  Takanori Hosokawa; Masayuki Kurosaki; Kaoru Tsuchiya; Shuya Matsuda; Masaru Muraoka; Yuichiro Suzuki; Nobuharu Tamaki; Yutaka Yasui; Toru Nakata; Takashi Nishimura; Shoko Suzuki; Ken Ueda; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Namiki Izumi
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

7.  Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures.

Authors:  Andrea Messori; Brigitta Badiani; Sabrina Trippoli
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

8.  The genotype analysis of the hepatitis C virus in Heilongjiang Province, China.

Authors:  Xue-Di Cheng; Hua-Feng Xu; Feng Wei; Li-Xin Jiang; Hai-Zhou Zhou
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

Review 9.  Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.

Authors:  Chang Seok Bang; Il Han Song
Journal:  BMC Gastroenterol       Date:  2017-04-04       Impact factor: 3.067

Review 10.  Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.

Authors:  Anne-Claire Desbois; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.